pharma.markets

  • HOME
  • Imprint

novartis

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

19/11/2020 MaP 0

• Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other […]

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

26/06/2020 MaP 0

• If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first […]

Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile

26/06/2020 MaP 0

• EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis • CHMP opinion based on two Phase […]

Novartis Resolves Legacy FCPA Investigations

25/06/2020 MaP 0

Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act […]

Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

20/06/2020 MaP 0

• FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of […]

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

07/06/2020 MaP 0

• Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to […]

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149)

06/06/2020 MaP 0

….versus a free combination of two existing inhaled treatments in uncontrolled asthma • Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a […]

Novartis provides update on FDA review of ofatumumab

03/06/2020 MaP 0

… a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis today announced that it has received notice from the US Food and […]

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

31/05/2020 MaP 0

• Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation […]

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

31/05/2020 MaP 0

• More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1 • Study […]

Novartis announces new late-breaking ofatumumab data

28/05/2020 MaP 0

…at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS) Rapid and profound depletion of B-cells contributed to […]

Translation

en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianja Japaneseko Koreanpt Portugueseru Russianes Spanish

Search

Categories

  • Age.related Degeneration
  • Animal health
  • Asthma
  • Cancer
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Humanitarian Aid
  • Imprint
  • Influenza
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • UN
  • Vaccines

Reports

  • Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
  • Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
  • EU doubles contribution to COVAX to €1 billion to ensure safe and effective vaccines for low and middle-income countries
  • In Vitro Study Published in The New England Journal of Medicine
  • Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

Archive

  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine

    25/02/2021 0
  • Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

    25/02/2021 0
  • Copyright European Commission 2021

    EU doubles contribution to COVAX to €1 billion to ensure safe and effective vaccines for low and middle-income countries

    20/02/2021 0
  • In Vitro Study Published in The New England Journal of Medicine

    17/02/2021 0
  • Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

    17/02/2021 0
Archives
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid biontech cancer commission companies coronavirus covid-19 covid19 crisis economy elpais.com eu europe european fda fight food global guarantee health hygiene italy links medical merck novartis pandemic pfizer production products recommendations region response roche safety scheme sector spain state statistics stats support vaccine

Copyright © 2021 | WordPress Theme by MH Themes